Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester

Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester of Pregnancy: a Case Report and Review of Literatures

Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester of Pregnancy

Study Overview

• Status: Completed
• Conditions: Listeria Monocytogenes
• Intervention / Treatment: Drug: Ampicillin Injection

Detailed Description

A 34-year-old nulliparous woman with 11 gestational weeks with flu-like illness was proved to be infection by Listeria monocytogenes, and then treated by intravenous ampicillin 2 g every 4 hours for 3 weeks. A healthy unaffected male baby was delivered at 41 weeks' gestation.

• Study Type: Observational
• Enrollment (Actual): 1

Contacts and Locations

Study Locations

• Taiwan
  • New Taipei, Taiwan, 220
    • Far Eastern Memorial Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

One pregnant woman with listeria monocytogenes bacteremia in the first trimester

Description

Inclusion Criteria:

• One pregnant woman with listeria monocytogenes bacteremia in the first trimester

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Successful treatment	A favorable outcome of maternal listeria infection in the first trimester may be anticipated. Besides, intravenous ampicillin with or without gentamicin should be a reasonable treatment option for maternal listeria infection in the first trimester.	1 month after delivery

Collaborators and Investigators

• Sponsor: Far Eastern Memorial Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 3, 2017
• Primary Completion (Actual): January 8, 2018
• Study Completion (Actual): February 2, 2018

Study Registration Dates

• First Submitted: August 10, 2017
• First Submitted That Met QC Criteria: August 10, 2017
• First Posted (Actual): August 15, 2017

Study Record Updates

• Last Update Posted (Actual): February 12, 2019
• Last Update Submitted That Met QC Criteria: February 9, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Bacterial Infections; Bacterial Infections and Mycoses; Sepsis; Bacteremia; Anti-Infective Agents; Anti-Bacterial Agents; Ampicillin
• Other Study ID Numbers: 106030-C

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No